🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with figures suggesting over 82 million infections each year. Particularly high rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Testing Data and Global Access

As per findings released by a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The research included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have shared hope. Access to a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.